John F. Modlin, MD

Selected Publications

Nasal and pharyngeal mucosal immunity to poliovirus in children following routine immunization with inactivated polio vaccine (IPV) in the United States of America.
Godin A, Connor RI, Degefu HN, Rosato PC, Wieland-Alter WF, Axelrod KS, Kovacikova G, Weiner JA, Ackerman ME, Chen EY, Arita M, Bandyopadhyay AS, Raja AI, Modlin JF, Brickley EB, Wright PF
J Infect Dis. 2024 May 29; pii: jiae264. doi: 10.1093/infdis/jiae264. Epub 2024 May 29.
PMID: 38809190

Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
Modlin JF, Bandyopadhyay AS, Sutter R
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S398-S404. doi: 10.1093/infdis/jiaa622.
PMID: 34590135

Mucosal immunity to poliovirus.
Connor RI, Brickley EB, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin JF, Bandyopadhyay AS, Wright PF
Mucosal Immunol. 2022 Jan;15(1):1-9. doi: 10.1038/s41385-021-00428-0. Epub 2021 Jul 8.
PMID: 34239028

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P
Lancet. 2021 Jan 2;397(10268):39-50. doi: 10.1016/S0140-6736(20)32541-1. Epub 2020 Dec 9.
PMID: 33308429

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Saez-Llorens X, Bandyopadhyay AS, Gast C, Leon T, DeAntonio R, Jimeno J, Caballero MI, Aguirre G, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, Fix A, Konz J, Clemens R, Costa Clemens SA, Ruttimann R
Lancet. 2021 Jan 2;397(10268):27-38. doi: 10.1016/S0140-6736(20)32540-X. Epub 2020 Dec 9.
PMID: 33308427

Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden.
Brickley EB, Connor RI, Wieland-Alter WF, Collett MS, Hartford M, Van Der Avoort H, Boesch AW, Weiner JA, Ackerman ME, McKinlay MA, Arita M, Bandyopadhyay AS, Modlin JF, Wright PF
BMJ Glob Health. 2019;4(4):e001613. doi: 10.1136/bmjgh-2019-001613. Epub 2019 Aug 28.
PMID: 31543993

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.
McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR
J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043.
PMID: 25316866

Atypical hand, foot, and mouth disease: a vesiculobullous eruption caused by Coxsackie virus A6.
Feder HM Jr, Bennett N, Modlin JF
Lancet Infect Dis. 2014 Jan;14(1):83-86. doi: 10.1016/S1473-3099(13)70264-0. Epub 2013 Nov 25.
PMID: 24287184

Inactivated polio vaccine and global polio eradication.
Modlin JF
Lancet Infect Dis. 2012 Feb;12(2):93-4. doi: 10.1016/S1473-3099(11)70312-7. Epub 2011 Nov 7.
PMID: 22071250

A fatal central nervous system enterovirus 68 infection.
Kreuter JD, Barnes A, McCarthy JE, Schwartzman JD, Oberste MS, Rhodes CH, Modlin JF, Wright PF
Arch Pathol Lab Med. 2011 Jun;135(6):793-6.
PMID: 21631275

View more publications on PubMed